How does this company make money?
The company earns the gap between what it receives from investing in duration-matched gilts and corporate bonds, and what it pays out in guaranteed monthly payments to retirees. Medical underwriting is what makes that gap profitable: by assessing each retiree's health, the company can price the liability side of that gap more precisely, hold less capital against it, and keep more of the difference as profit.
What makes this company hard to replace?
Pension scheme trustees cannot quickly move to a different provider even if they wanted to — the Prudential Regulation Authority takes 12 to 18 months to approve any new bulk annuity provider, which limits the pool of alternatives at any given time. Trustees also have to carry out extensive checks on a new counterparty's financial strength before signing, which takes significant time and resource. And once individual retirees are in a guaranteed lifetime payment contract, there are no transfer provisions — they cannot move their annuity to another provider at all.
What limits this company?
Every new pension block the company takes on requires a fresh, transaction-specific capital reserve under Solvency II rules. That capital cannot be stretched or shared across deals — each new block needs its own pot. So the total volume of business the company can write at any moment is capped by how much regulatory capital it has available, and that ceiling does not get easier to hit as the company grows.
What does this company depend on?
The company cannot operate without five things: the UK gilt market, which supplies the government bonds used to match future payment obligations; the Solvency II regulatory framework and Prudential Regulation Authority supervision, which set the rules for how capital reserves are calculated; the medical underwriting data systems used to assess individual retiree health; the Lloyd's of London reinsurance market, where the company transfers some of its longevity risk; and UK defined benefit pension scheme trustees, who are the counterparties in every transaction.
Who depends on this company?
UK defined benefit pension schemes rely on this company as one of the few routes available to fully transfer their retirees' longevity risk — if the company stopped writing deals, those schemes would have fewer exit options. Individual annuitants aged 55 and over who hold medically-enhanced guaranteed income products would lose access to those contracts. Lloyd's longevity reinsurers would also lose a significant source of UK longevity risk to absorb.
How does this company scale?
The medical underwriting algorithms and actuarial pricing models can be applied to each new transaction without the cost of building them again — that part gets cheaper per deal over time. What does not get cheaper is capital. Solvency II requires a separate, linearly sized capital reserve for every new liability block, so the capital burden grows in direct proportion to the business written and cannot be made more efficient at larger scale.
What external forces can significantly affect this company?
Bank of England interest rate decisions directly affect gilt yields, which are the foundation of the asset-liability matching calculation — a shift in rates changes the economics of every deal. If UK longevity improves faster than the actuarial assumptions built into existing contracts, retirees live longer and payment obligations grow beyond what was priced in. Brexit has also complicated access to EU reinsurance markets, which affects the company's ability to transfer longevity risk through Lloyd's and other reinsurers with European operations.
Where is this company structurally vulnerable?
If the team of specialist actuaries behind the health assessment system left, or if the Prudential Regulation Authority required the underwriting methodology to be revalidated from scratch, the company would lose its ability to size Solvency II reserves more tightly than anyone else. Without that edge, the profit spread collapses and new bulk annuity deals can no longer be written at a profit.
CompanyGraph